RxDoctor Payments Data

James Maher, MD

Cardiovascular Disease · Rock Hill, SCNPI 1235334145

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations.

$6,086in general payments, 2019–2025

Across 176 payments — averaging $34.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$772
  • Novartis$617
  • E.r. Squibb & Sons, L.L.C.$330
  • Penumbra, Inc.$285
  • Bayer$280
  • plus $3K from 26 others
$39,133in research payments, 2019–2025

Across 2 payments — averaging $19,566 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$39K

What the payments were for

  • Food & beverage$6,086100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,086 in reported general payments places this provider in the 60th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,053,710
Medicare patients
1,490
Services billed
7,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban449$478,345
CamzyosMavacamten31$230,716
EntrestoSacubitril/Valsartan102$138,565
FarxigaDapagliflozin Propanediol111$121,002
JardianceEmpagliflozin128$105,334
XareltoRivaroxaban71$79,921
Repatha SureclickEvolocumab38$37,548
BrilintaTicagrelor17$18,665
VerquvoVericiguat13$15,128
Rosuvastatin Calcium466$5,566
Metoprolol Succinate442$5,252
Clonidine29$4,431
Ranolazine ErRanolazine65$4,354
Flecainide Acetate110$4,226
Losartan Potassium288$2,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$195$478,345449 claims
E.r. Squibb & Sons, L.L.C.Camzyos$330$230,71631 claims
AstraZenecaFarxiga, Brilinta$275$139,666128 claims
NovartisEntresto$617$138,565102 claims
Boehringer IngelheimJardiance$139$105,334128 claims
Johnson & JohnsonXarelto$16$79,92171 claims
MerckVerquvo$133$15,12813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →